Latrepirdine for Alzheimer's disease.

ABSTRACT:

Background

Current treatments for Alzheimer's disease (AD) provide modest symptomatic relief but do not slow the progression of the disease. Latrepirdine may modulate several targets involved in AD pathology, including lipid peroxidation, mitochondrial permeability, voltage-gated calcium ion channels as well as neurotransmitter receptor activity, and thus potentially represents both a symptomatic and disease-modifying intervention. Several randomized, placebo-controlled trials have sought to evaluate the effect of latrepirdine on cognition, function and behaviour in patients with AD.

Objectives

To evaluate the efficacy and safety of latrepirdine for the treatment of AD.

Search methods

We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvem

SUBMITTER: Chau S 

PROVIDER: S-EPMC7388906 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature